OCULIS
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
OCULIS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2003-01-01
Address:
ReykjavÃk, Gullbringusysla, Iceland
Country:
Iceland
Website Url:
http://www.oculis.com
Total Employee:
11+
Status:
Active
Contact:
+354 546-4440
Email Addresses:
[email protected]
Total Funding:
94.36 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Apache
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Hyfinity Investments
Hyfinity Investments investment in Series C - Oculis
Bay City Capital
Bay City Capital investment in Series C - Oculis
Nan Fung Life Sciences
Nan Fung Life Sciences investment in Series C - Oculis
BVCF
BVCF investment in Series C - Oculis
Tekla Capital Management
Tekla Capital Management investment in Series C - Oculis
Silfurberg
Silfurberg investment in Series C - Oculis
Brunnur Ventures
Brunnur Ventures investment in Series C - Oculis
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series C - Oculis
VI Partners
VI Partners investment in Series C - Oculis
Novartis Venture Fund
Novartis Venture Fund investment in Series C - Oculis
Key Employee Changes
Official Site Inspections
http://www.oculis.com Semrush global rank: 3.27 M Semrush visits lastest month: 5.03 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago